Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of New Drugs Director John Jenkins reassured panel members of the agency’s ability to assess civil penalties or cite a drug for misbranding if sponsors fail to meet post-market study obligations.